Prescription Support System for Antimicrobial Use in Belgian Primary Care
NCT ID: NCT07347015
Last Updated: 2026-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
48 participants
INTERVENTIONAL
2025-12-21
2027-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study evaluates the impact of a digital Prescription Support System (PSS) designed to support antimicrobial prescribing in Belgian primary care. The PSS provides guideline-based recommendations derived from the Belgian BAPCOC guidelines for common infections in ambulatory care. Recommendations are presented through a user-friendly decision tree that is integrated into existing electronic health record systems and can be consulted during routine care.
The study is embedded within the national implementation strategy of the PSS coordinated by the National Institute for Health and Disability Insurance (RIZIV-INAMI). A stepped-wedge cluster randomized design is used, in which participating general practices transition sequentially from usual care to access to the PSS over four predefined implementation steps. This approach ensures that all participating practices eventually receive access to the system while allowing comparisons over time.
The primary objective is to assess whether implementation of the PSS is associated with changes in antibiotic prescribing in Belgian general practice. Prescribing outcomes are measured using routinely collected indicators from the Belgian Antibiotic Barometer, including overall antibiotic prescribing rates and the use of broad- versus narrow-spectrum antibiotics. Secondary objectives include assessing the usability and acceptability of the PSS among clinicians and identifying factors that influence its adoption in daily practice. The study will also monitor potential unintended consequences, such as changes in workflow or concerns about underprescribing.
Findings from this study will inform future decisions regarding further optimization and wider implementation of the PSS in Belgian primary care.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Better Antibiotic Prescribing Through Action Research
NCT03082521
Routine Prescription Feedback and Peer Comparison to Lower Antibiotic Prescriptions in Primary Care
NCT01773824
Providing Antibiotic Prescribing Feedback to Primary Care Physicians: The Ontario Program To Improve AntiMicrobial USE
NCT03776383
Evidence-based Laboratory Test Order Sets in Primary Care
NCT02950142
Studying the Impact of a Medication Use Evaluation by the Community Pharmacist
NCT03179722
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This implementation project builds upon a previously conducted mixed-methods implementation study evaluating the usability of a PSS, which was approved by the Ethical Review Board UZ KU Leuven (Onderwijs-Begeleidingscommissie) on 27 September 2024 (MP031770).
The PSS under study contains the current recommendations for the proper use of antimicrobial agents for common infections in ambulatory care in Belgium. In other words, it represents the BAPCOC guidelines in a digital and user-friendly environment, by using a decision tree. Advice for the following diagnoses (ICPC-2 codes) is included in the PSS: sore throat (R21, R74), pertussis (R71), common cold (R74), acute rhinosinusitis (R75), acute bronchitis / bronchiolitis (R78), influenza (R80), pneumonia (R81), ear pain (H01), otorrhea (H04), acute otitis media (H71), acute epiglottitis (R77), acute exacerbations of chronic obstructive pulmonary disease, aspiration pneumonia (R81), laryngitis stridulosa (R77), acute cystitis (U71), acute prostatitis (Y73), acute pyelonephritis (U70), acute vulvovaginitis (X84), asymptomatic bacteriuria, epididymo-orchitis (Y74), genital herpes (Y72, X90), partner treatment and treatment of asymptomatic sexually transmitted infections, pelvic inflammatory disease (X74), syphilis (X70, Y70), and urethritis (U72).
This PSS was developed as part of the Belgian National Action Plan on AMR by the Federal Public Service Health, Food Chain Safety and Environment and the National Institute for Health and Disability Insurance (NIHDI; RIZIV-INAMI), in collaboration with various experts and stakeholders, including physicians, infectiologists, hygienists, policymakers, guideline developers, and software developers. The company Smals, under instruction of RIZIV-INAMI, developed the software for this application in close collaboration with the RIZIV-INAMI working group. Guideline recommendations regarding appropriate prescribing of antimicrobials in ambulatory care were converted into decision rules, which serve as the knowledge source for the PSS.
Digital education offers several advantages, such as easy access without time or location constraints, varying possible forms and levels, and the ability to disseminate evidence on a large scale. Previous research has shown that standalone web- or smartphone-based applications in this context have the potential to increase physicians' knowledge of antimicrobials and guideline recommendations, potentially improving guideline adherence.
In Belgium, antibiotic use in ambulatory care is closely monitored through the Antibiotic Barometer, a national surveillance system coordinated by the Academic Centre of General Practice of KU Leuven and financed by the National Institute for Health and Disability Insurance (RIZIV-INAMI). The Antibiotic Barometer was approved by the Sociaal-maatschappelijke Ethische Commissie (SMEC; G-2023-6352) and provides quarterly feedback to general practices based on routine health insurance claims data.
This study evaluates the implementation and impact of the PSS in routine Belgian primary care using a stepped-wedge cluster randomized trial design. Participating general practices are recruited to ensure broad representation across Belgian primary care. General practices constitute the unit of randomization and are randomly allocated to one of four predefined implementation steps. All practices start in a control condition without access to the PSS and transition once to the intervention condition according to their assigned step. Each implementation step lasts three months, after which practices retain access to the PSS for the remainder of the study period. By the end of the study, all participating practices will have received access to the intervention.
Data for this study are derived from routine sources and handled within the secure data infrastructure of KU Leuven. Prescribing data obtained via the Antibiotic Barometer are aggregated and pseudonymized at practice level prior to analysis, ensuring that individual patients cannot be identified. Data linkage, storage, and analysis are conducted in accordance with applicable data protection regulations. Quantitative and qualitative analyses are used to evaluate both the effectiveness and implementation of the PSS in real-world primary care. Findings from this study will inform future policy decisions regarding national rollout, optimization, and long-term integration of the PSS within Belgian antimicrobial stewardship strategies.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
Primary and secondary outcomes are based on routinely collected indicators from the Belgian Antibiotic Barometer. Analyses assess changes in antibiotic prescribing over time and compare practices by intensity of PSS use, derived from application log files. A process evaluation will be embedded, consisting of semi-structured interviews using a topic guide and log file analysis to assess implementation fidelity, reach and mechanisms of impact.
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control: Usual Care
In the control arm, general practices will provide usual care, left at the discretion of the treating general practitioner.
Apart from the general information or training session attended by all participating physicians prior to recruitment and randomization, practices in the control arm will not receive access to the Prescription Support System (PSS) or any additional decision support tools.
General practitioners in the control arm are expected (but not forced) to follow the Belgian guidelines for antimicrobial prescribing, as described in the BAPCOC national guidelines.
No interventions assigned to this group
Intervention: access to PSS
Prescription Support System (PSS) Providing guideline-based recommendations for antimicrobial prescribing in ambulatory care.
Prescription Support System (PSS)
General practices in this arm have access to the Prescription Support System (PSS), a digital clinical decision support tool integrated into the electronic health record that provides guideline-based recommendations for antimicrobial prescribing in ambulatory care. The PSS presents recommendations derived from the Belgian BAPCOC guidelines using a structured decision-tree format. During eligible consultations, the PSS can be consulted by the general practitioner to support clinical decision-making regarding antibiotic prescribing. The tool provides information on recommended antibiotic choice, dosage, and duration, as well as guidance on situations in which antibiotic treatment is not indicated. Practices transition to this arm according to the stepped-wedge design and retain access to the PSS for the duration of the study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Prescription Support System (PSS)
General practices in this arm have access to the Prescription Support System (PSS), a digital clinical decision support tool integrated into the electronic health record that provides guideline-based recommendations for antimicrobial prescribing in ambulatory care. The PSS presents recommendations derived from the Belgian BAPCOC guidelines using a structured decision-tree format. During eligible consultations, the PSS can be consulted by the general practitioner to support clinical decision-making regarding antibiotic prescribing. The tool provides information on recommended antibiotic choice, dosage, and duration, as well as guidance on situations in which antibiotic treatment is not indicated. Practices transition to this arm according to the stepped-wedge design and retain access to the PSS for the duration of the study.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willingness to use and activate the PSS by giving consent.
* Agreement to participate in the study, provided signed informed consent form is in place.
Exclusion Criteria
* Practices already using a similar PSS or participating in overlapping projects.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute for Health and Disability Insurance (RIZIV-INAMI)
UNKNOWN
INTEGO - Flemish General Practice Morbidity Registry (KU Leuven)
UNKNOWN
SMALS
UNKNOWN
KU Leuven
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jan Verbakel
Prof. Dr. Jan Y. Verbakel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GPs associated with KU Leuven
Leuven, Vlaams-Brabant, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Madar R, Ugon A, Ivankovic D, Tsopra R. A Web Interface for Antibiotic Prescription Recommendations in Primary Care: User-Centered Design Approach. J Med Internet Res. 2021 Jun 11;23(6):e25741. doi: 10.2196/25741.
Delory T, Jeanmougin P, Lariven S, Aubert JP, Peiffer-Smadja N, Boelle PY, Bouvet E, Lescure FX, Le Bel J. A computerized decision support system (CDSS) for antibiotic prescription in primary care-Antibioclic: implementation, adoption and sustainable use in the era of extended antimicrobial resistance. J Antimicrob Chemother. 2020 Aug 1;75(8):2353-2362. doi: 10.1093/jac/dkaa167.
Helou RI, Foudraine DE, Catho G, Peyravi Latif A, Verkaik NJ, Verbon A. Use of stewardship smartphone applications by physicians and prescribing of antimicrobials in hospitals: A systematic review. PLoS One. 2020 Sep 29;15(9):e0239751. doi: 10.1371/journal.pone.0239751. eCollection 2020.
Fralick M, Haj R, Hirpara D, Wong K, Muller M, Matukas L, Bartlett J, Leung E, Taggart L. Can a smartphone app improve medical trainees' knowledge of antibiotics? Int J Med Educ. 2017 Nov 30;8:416-420. doi: 10.5116/ijme.5a11.8422.
Kyaw BM, Tudor Car L, van Galen LS, van Agtmael MA, Costelloe CE, Ajuebor O, Campbell J, Car J. Health Professions Digital Education on Antibiotic Management: Systematic Review and Meta-Analysis by the Digital Health Education Collaboration. J Med Internet Res. 2019 Sep 12;21(9):e14984. doi: 10.2196/14984.
1. BAPCOC - Belgische Gids voor Anti-Infectieuze Behandeling in de Ambulante Praktijk 2022. Available from: https://www.bcfi.be/nl/chapters/12?frag=8000010. Accessed 11 July 2024.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MP037810
Identifier Type: OTHER
Identifier Source: secondary_id
MP037810
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.